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The concept of a CpG island methylator phenotype, or CIMP, quickly became the focus of several colorectal cancer studies
describing its clinical and pathological features after its introduction in 1999 by Toyota and colleagues. Further characterization
of CIMP in tumors lead to widespread acceptance of the concept, as expressed by Shen and Issa in their 2005 editorial, “CIMP, at
last.” Since that time, extensive research eﬀorts havebrought great insightsinto the epidemiology and prognosisofCIMP+ tumors
and other epigenetic mechanisms underlying tumorigenesis. With the advances in technology and subsequent cataloging of the
human methylome in cancer and normal tissue, new directions in research to understand CIMP and its role in complex biological
systems yield hope for future epigenetically based diagnostics and treatments.
1.Introduction
In the October 29, 2010 issue, Science turned the spotlight
on epigenetics—a term that encompasses histone modiﬁ-
cation, nucleosome location, noncoding RNA, and DNA
methylation. Epigenetic processes do not involve changes
to DNA sequence but rather are self-propagating molecular
signatures that are potentially reversible, unlike changes in
geneticinformation[1].DNAmethylationisthemostwidely
studied epigenetic marker [2]. The discovery of global DNA
hypomethylation in human tumors was followed by the
identiﬁcation of hypermethylated tumor-suppressor genes
and recently, inactivation of microRNA (miRNA) by DNA
methylation also has been described [3–5]. Growing interest
in epigenetic systems stems from an inability to determine
causative genetic variants in many disorders. It is hoped that
a better understanding of these systems may provide insight
into our understanding of complex diseases such as cancer.
Approximately half of all protein-encoding genes in the
human genome contain CG-rich regions in their promoters
or CpG islands. Aberrant DNA methylation, in the form
of hypermethylation of CpG islands, results in repression
of transcription in tumor suppressor genes. For example,
inactivation of the mismatch repair gene MLH1 by pro-
moter methylation is the molecular basis for microsatellite
instability in sporadic microsatellite unstable colon cancers
[6]. This phenomenon of tumor alteration via epigenetic
silencing associated with dense hypermethylation of CpG
islands, and their complex interplay with modiﬁcations
in histone structure, provides an alternate mechanism to
genetic inactivation of tumor suppressor genes via loss
or mutation [2] .T h ep r e s e n c eo fw i d e s p r e a dC p Gi s l a n d
methylation in a tumor is termed the CpG island methylator
phenotype, or CIMP, and this paper is focused on this
speciﬁc aspect of epigenetics.
2.CIMP inColorectalCancer
The role of CIMP in colorectal carcinogenesis was originally
postulated in 1999 by Toyota et al. [7]. Their pioneering
study distinguished between age-related and cancer-related
methylation and deﬁned CIMP in terms of the latter. Recog-
nition of CIMP as a phenomenon in colorectal cancer is rel-
atively recent; more than a decade earlier, in 1988, Vogelstein
and colleagues developed a model that hypothesized that2 Pathology Research International
colorectalneoplasiaoccursfromaseriesofgeneticalterations
that includes activation of oncogenes and inactivation of
tumor suppressor genes [8]. The concept of an epigenetic
etiology in cancer introduced in the late 1990s was met with
somecontroversy andresistance in theﬁeldofcarcinogenesis
[6, 9, 10]. However, the existence of CIMP has since
gained wide acceptance, as the epidemiology characterizing
this epigenetic alteration and its utility in understanding
carcinogenic pathways support its signiﬁcance in colorectal
cancer biology [11–14].
Most sporadic microsatellite unstable colon tumors are
CIMP positive, whereas CIMP is uncommon in Lynch sy-
ndrome-associated cancers which exhibit microsatellite
instability (MSI), indicative of distinct underlying molecular
processes [13,15].Basedonanumberofrelativelylargecase-
controlandprospectivecohortstudies, ∼30–40%ofsporadic
proximal-site colon cancers are CIMP positive, compared
to 3–12% of distal colon and rectal cancers [16–21]
as illustrated in Figure 1.T h u sC I M Pi ss i g n i ﬁ c a n t l ym o r e
frequent in tumors of the proximal colon, and this is
independent of MSI status. CIMP is also associated with
BRAF mutations in both microsatellite stable and unstable
colon cancers [11, 18, 20]. CIMP is observed in proximal
hyperplastic (serrated) polyps, suggesting this lesion may
be a precursor to unstable tumors (and perhaps stable
tumors) in the CIMP high pathway [22]. Once thought to
lackpotential formalignant progression, hyperplastic polyps
are now considered to represent a heterogeneous group,
most of which harbor BRAF mutations and some of which
exhibit epigenetic alterations (both uncommon in colorectal
adenomas). A subset of hyperplastic polyps has been deﬁned
by architectural features and renamed sessile serrated polyps
(or sessile serrated sessile adenomas). Most of these polyps
are right-sided and many show CIMP, supporting the notion
that they may be a precursor lesion for CIMP high tumors
[23, 24].
Some case-control and cohort studies have reported
a poor prognosis associated with CIMP in combination with
microsatellite stable tumors [19, 25–27], although this may
reﬂect the co-occurrence of BRAF V600E mutations, which
have been associated with signiﬁcantly poorer survival in
colon cancer [28, 29]. Relatively minor eﬀects of CIMP on
prognosis suggest that the eﬀect of mutations in BRAF on
survival in stabletumors is not dependent on CIMP [16, 28].
Indeed, Ogino et al. reported that CIMP-high appears to
be an independent predictor of a low colon cancer-speciﬁc
mortality [30]. These results suggest the need for a large
sample size to determine the relative contributions of BRAF
a n dC I M Po np r o g n o s i s .
3.Characterizationof CIMP
In contrast to the relatively straightforward determination of
MSI tumor status, a consensus as to the optimal panel of
CpG sites for CIMP determination is only starting to take
shape (Table 1). Diﬀerent panels may yield slightly diﬀerent
results, although a strong relationship to the presence of
a BRAF V600E mutation is consistently observed with all
panels. The so-called “classic” panel of Park et al. utilized to
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Figure 1: In colorectal cancer, CIMP+ occurs more frequently in
tumors of the proximal colon (Figure 1(a)) and less frequently in
tumors of the distal colon and rectum (Figure 1(b)). An approx-
imate distribution of genetic and epigenetic tumor alterations is
shown.
assess CIMP status consists of CpG sites in MLH1, CDKN2A
(p16), and methylated in tumors (MINTS) 1, 2, and 31
[31]. It has been suggested that there are two general types
of CIMP in sporadic tumors: CIMP high, related to BRAF
mutations and MLH1 methylation; and CIMP low, related
to KRAS mutations [12, 32, 33]. Tumors characterized
as CIMP positive (CIMP+) based on the classic panel
includebothCIMPhighand CIMPlowcategories;therefore,
a subset of CIMP+ associates with BRAF and another with
KRAS mutations, somewhat surprising given mutations in
these genes are typically mutually exclusive since both are
members of the ras signal transduction pathway [6, 11].
Based on a systematic screen of 195 CpG sites and
an unsupervised two-dimensional cluster analysis, Weisen-
berger et al. proposed a robust alternative to the classic panel
to classify CIMP+ tumors consisting of CACNA1G, IGF2,
NEUROG1, RUNX3, and SOCS1 [13]; CIMP as deﬁned
by this panel did not show a relationship to KRAS.U s i n g
quantitative real-time PCR, Ogino et al. [34] selected a panel
ofmarkers todistinguish high fromlow levelsofmethylation
includingMLH1and CDKN2A,and three markersthatdiﬀer
from theclassic panel: CACNA1G, CRABP1,a n dNEUROG1.
Shenet al.examined geneticmarkers(BRAF, KRAS)an depi-
genetic markers at 27 promoter-associated CpG sites using
clustering analysis to identify two distinct CIMP+ groups:
CIMP1, characterized by MSI+ and BRAF mutations, and
MINT1, MLH1, RIZ1, TIMP3 methylation; and CIMP2,
characterized by KRAS mutationsand methylation of several
MINT markers [33].
Using structural equation modeling to construct causal
models of CIMP and locus-speciﬁc CpG island methylation
and a large database of colorectal cancers, Tanaka et al.
showed the correlation structures of 16 methylation markers
and CIMP status diﬀered between BRAF mutated, KRAS
mutated, and wildtype BRAF/KRAS tumors [35]. They
suggested a possible role of these mutations diﬀerentially
modifying the propensity for locus-speciﬁc methylation at
the cellular level. To examine the question of whether or
not BRAF V600E plays a causal role in the development ofPathology Research International 3
Table 1: A history of CIMP panels used to assess CpG island methylation in colorectal cancer.
Study CIMP panel markers Notes
Toyota et al. [7] CDKN2A (p16), MINT1, MINT2, MINT12, MINT17,
MINT25, MINT27, MINT31, MLH1, THBS1
Pioneering work to identify markers that distinguish
CIMP from age-related methylation
Park et al. [31] CDKN2A, MINT1, MINT2, MINT31, MLH1 So-called “classic” or traditional panel
Weisenberger et al. [13] CACNA1G, IGF2, NEUROG1, RUNX3, SOCS1 “New” panel based on stepwise screen of 195 markers
Ogino et al. [34] CACNA1G, CDKN2A, CRABP1, MLH1, NEUROG1 Selected markers to distinguish high-level from
low-level methylation
Shen et al. [33]
CIMP1: MINT1, MLH1, RIZ1, TIMP3, BRAF
mutation; CIMP2: MINT2, MINT27, MINT31,
Megalin, KRAS mutation
Examined 27 CpG sites, proposed optimal epigenetic
and genetic markers to identify CIMP1, CIMP2, or
CIMP-
Tanaka et al. [35]
CACNA1G, CDKN2A, CHFR, CRABP1, HIC1, IGF2,
IGFBP3, MGMT,M I N T 1 ,M I N T 3 1 ,NEUROG1, p14,
RUNX3, SOCS1, WRN
Correlation structures of markers and CIMP diﬀer by
KRAS and BRAF status
Ang et al. [36] Total of 202 CpG sites diﬀerentially methylated
between tumor and normal
Comprehensive DNA methylation proﬁling in 807
cancer genes
Kaneda and Yagi [37]
Group 1: IGF2, LOX, MINT1, MINT2, MINT31,
MLH1, RUNX3, SOCS1; Group 2: ADAMTS1,
DUSP26, EDIL3, ELMO1, FBN2, HAND1, IGFBP3,
NEUROG1, RASSF2, STOX2, THBD, UCHL1
Comprehensive DNA epigenotyping of genomewide
regions indentiﬁed two groups (high and intermediate
to low methylation)
CIMP, Hinoue et al. determined 100 CIMP-associated CpG
sites and examined changes in DNA methylation in eight
stably transfected clones over multiple passages [38]. They
observed that BRAF was not suﬃcient to induce CIMP in
their system.
In contrast to evaluation of relatively small sets of CIMP
markers, comprehensive DNA methylation proﬁling and
unsupervised hierarchical clustering were recently used to
identify several CpG sites that were diﬀerentially methylated
between tumor and normal tissue [36]. Using a similar
approach, the use of two methylation panels as classiﬁers
of colorectal cancer has been proposed: the ﬁrst to identify
highly methylated tumors (strongly correlated with BRAF)
and a second to distinguish between intermediate (associ-
ated with KRAS) and low methylation groups [37]. Since
epigenetic therapy is in clinical use or trials for several
cancers,eﬃcientmethodsforepigeneticproﬁlingareneeded;
Kondo and Issa provide a summary of available proﬁling
techniques and their features [39]. As approaches to CIMP
characterization in colorectal cancer continue to evolve, it is
clearthatBRAF andKRASoncogenemutationswillcontinue
to reﬁne any deﬁnition of CIMP. Although characterization
of CIMP status dependson methylation markers and criteria
used, classiﬁcation of tumors by both CIMP and MSI status
recently proposed by Jass [40] and further reﬁned by Ogino
and Goel [14] has become an increasingly common strategy
to deﬁne the pathological and clinical features of colorectal
cancer.
4.EpidemiologyofCIMP
4.1. Characteristics. Relationships between CIMP and clin-
icopathologic features of colorectal tumors that have been
widely reported include proximal location, older age at
diagnosis, female gender, poor tumor diﬀerentiation, MSI
(CIMP high cancer), BRAF mutations,K R A Smutations
(microsatellite stable cancer), and wildtype TP53 [11, 13, 16,
17, 34, 41]. Based on a large Australian cohort, English et al.
reported thatindividualsofsouthernEuropeanethnicityhad
lower risk of CIMP and BRAF mutation than those with
origins in northern Europe [21].
U s i n ga c t u a ld a t aa n dac l a s s i ﬁ c a t i o nt r e em e t h o dt o
visualize carcinogenic pathways, Slattery et al. suggested that
unique mutational pathways to colon and rectal cancer likely
exist [18]. This method describes the probability of devel-
oping various alterations in proximal colon, distal colon, or
rectal tumors given previously acquired mutations. Using
bootstrap resampling, theprobabilitiesofdevelopingspeciﬁc
mutations diﬀered across tumor sites. For example, the esti-
mated proportion of tumors that will develop methylation
at CpG sites decreased as one goes from proximal colon to
rectal cancers. Regardless of site, a methylation pathway in
which BRAF is subsequently acquired independent of MSI
or MLH1 methylation was predicted. This work supports
previous observations that link CIMP and BRAF mutation,
independent of MSI status [11, 12].
4.2. Smoking. T h ep r e s e n c eo fm e t h y l a t i o ni nh u m a nm a l i g -
nancies bears a relationship toa history of cigarette smoking.
Cigarette smoking has been associated with CpG island
methylation within the bronchial epithelium of smokers and
in lung cancer, and activation of the aromatic hydrocarbon
receptor by cigarette smoke has been associated with CpG
methylation [42–44]. A signiﬁcant relationship has been
reported between cigarette smoking and CIMP (and closely
related mutations in BRAF) in colon and rectal carcinomas
in both prospective cohort and case-control studies [45–48].
Interestingly, the relationship between smoking and CIMP4 Pathology Research International
provides an explanation for the previously observed associ-
ation between cigarette smoking and MSI, as most of these
tumors also exhibit CIMP [49]. Evidence also suggests that
cigarette smoking (related to CIMP and BRAF)m a yb e
associatedwithhyperplasticpolypsratherthanadenomatous
polyps; as mentioned above, a subset of hyperplastic polyps
has been hypothesized to be the precursor to CIMP high
colorectal carcinomas [50].
4.3. Other Risk Factors. S Adenosylmethionine (SAM), the
universal donor of methyl groups in humans, and S Adeno-
sylhomocysteine (SAH), the product of and an inhibitor
of DNA methyltransferase (DNMT) enzymes, provide con-
nections between folate metabolism and DNA methylation
[51]. It has been hypothesized that diets low in folate and
high in alcohol intake may disturb DNA methylation, which
may result in global DNA hypomethylation concurrently
with a greater risk of cancers with CpG island methylation
[52, 53]. In contrast, other studies have shown that global
DNA hypomethylation is inversely correlated with CIMP
and may represent diﬀerent pathways to colorectal cancer
[54, 55]. Studies generally do not support a unique role
for alcohol and folate in CIMP+ tumors [56, 57], although
genetic polymorphisms in MTHFR 1298A > C (rs1801131),
interacting with diet, and TCN2 776G > C (rs1801198) may
be involved in the development of highly CpG-methylated
colon and rectal cancers [58–60]. Conversely, MTHFR
1298A > C was not associated with CIMP+ tumors in
the Netherlands cohort study [61]. Polymorphisms in DNA
repair genes have been implicated in CIMP-positive colon
cancer [62, 63]. A promoter polymorphism in MLH1 (−93G
> A) was associated with CIMP, MLH1 methylation, and
BRAF mutations in unstable sporadic colon tumors and not
instabletumors,suggesting thegeneticvariant maybeacting
at a relatively late stage of carcinogenesis to drive CIMP-
positive tumors down the microsatellite instability pathway
[63].
Overexpression of DNMT3B has been shown to be a risk
factor for the development of CIMP in colorectal cancer
[64, 65]. DNMT3B is important in establishing and main-
taining genomic methylation patterns, and overexpression
in mice can induce tumors with methylation in speciﬁc
CpG islands. Recent ﬁndings indicate that DNA methylation
changes occur sequentially during tumor progression, and
DNMT3B expression levels increase during this progression
[66].
The future of CIMP in colorectal cancer research may
well take place in the evolving trans- and interdisciplinary
ﬁeld of “molecular pathological epidemiology” outlined by
Ogino et al, which is designed to elucidate how genetic
factors and lifestyle exposures interact with speciﬁc molec-
ular subtypes of cancer [67]. Hughes et al. reported that
severe caloric restriction was associated with decreased risk
of developing a tumor characterized by CIMP. This study
provides a potential link between early life conditions and
epigenetic changes that later inﬂuence colorectal cancer
development [68]. The work of Slattery et al. regarding dif-
ferences in the etiologies of rectal-site and colon-site tumors,
and the inﬂuence of genetic factors in the inﬂammatory
pathway in the etiology of CIMP in both, is an example of
this approach [69, 70].
5.Emerging TrendsinCIMP Research
Although aberrant DNA methylation of promoter CpG
islandsincancergenesaswell asrepressivechromatin arefre-
quently involved in gene inactivation during tumorigenesis,
the mechanisms underlying CIMP are poorly understood.
Patterns of hypermethylation are speciﬁc to tumor type, and
it is unclear why certain regions become hypermethylated;
however, mapping of the human methylome as a result of
technological advances has expanded our understanding of
epigenetic mechanisms [71]. Inactivation of particular genes
may confer a growth advantage, resulting in clonal selection
[72]. Another possibility is that long-range epigenetic silenc-
ing by DNA methylation can span chromosome regions of
1Mb in colorectal cancer, resembling the loss of heterozy-
gosity often observed in tumors [73]. In a large cohort of
sporadic colorectal cancers, Wong et al. reported a strong
relationship between long-range silencing of chromosome
region 3p22 and CIMP+ tumors [74].
Recent ﬁndings suggest that most DNA methylation
alterations in colon cancer occur in CpG island shores,
sequences up to 2kb distant from CpG islands [75]. Hyper-
methylated CpGshores appearclosertotheirassociated CpG
islands, while hypomethylated shores occur further away
from their associated islands and resemble noncolon normal
tissues. These ﬁndings are consistent with an epigenetic
progenitor model of cancer, in which epigenetic alterations
aﬀecting tissue-speciﬁc diﬀerentiation are the predominant
mechanism by which epigenetic changes cause cancer. Alter-
native transcription may be a function of diﬀerential DNA
methylation during diﬀerentiation, and one role of altered
methylation in cancer may be to disrupt regulatory control
of speciﬁc promoter usage [75].
Previous studies suggest a general model in which genes
reposition away from the heterochromatin when activated
and gravitate to heterochromatin when silenced [76]. How-
ever, Easwaran et al. demonstrated that aberrant silencing
of cancer-related genes occurred without requirement for
their being positioned at heterochromatic domains using
immunostaining for active/repressive chromatin marks and
ﬂuorescence in-situ hybridization in CRC cell lines. Further-
more, CpG hypermethylation, even associated with long-
range silencing of nearby genes, occurred independently of
their heterochromatic or euchromatic location [77]. These
ﬁndings have important implications for understanding
relationships between gene expression patterns and nuclear
organization in cancer.
Another area under investigation is the understanding of
mechanisms underlying which tumor suppressor genes are
targeted for inactivation in cancer. Studies suggest a stem
cell origin linked to epigenetic control of gene expression
patterns in precursor cells regulated by constituent proteins
in PcG repressive complexes including Polycomb Repressive
Complex PRC1 [78, 79]. It was subsequently shown that
sustained expression of the PRC1 protein, CBX7 along withPathology Research International 5
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Figure 2: A decade of epigenetic research in colorectal cancer
(CRC)hasledtowidespreadrecognitionandacceptance oftheCpG
Island Methylator Phenotype.
other proteins, targets gene promoters in a progenitor-like
embryonic tumor cell resulting in a cell population that
models epigenetic characteristics of adult cancer (including
aberrant CpG-island methylation) via inhibited response to
diﬀerentiation cues [80].
DNA methylation markers have potential clinical use
as diagnostic and prognostic tools. Hypermethylation of
CpG islands can serve as a biomarker of cancer cells in
t u m o rb i o p s i e sa n do t h e rs p e c i m e n s .F o re x a m p l e ,q u a n t i t a -
tive assessment of methylation in CIMP-speciﬁc promoters
of MLH1, WRN, and other DNA-repair genes in colon
tumors, in comparison to paired normal tissues, may predict
response to treatment [2]. Proﬁles of miRNA expression
also diﬀer between tumor and normal tissues; silencing of
miR-124a in colon cancer cells activates expression of the
oncogene CDK6 [5]. Continued research involving detailed
DNA methylomes in healthy and diseased tissues will help
distinguish causal epigenetic alterations from “bystander
changes” which are a consequence of cellular processes [71].
Unlike mutations in DNA sequence, epigenetic alter-
ations such as CpG Island hypermethylation are poten-
tially reversible by “reawakening” silenced tumor suppressor
genes. Two nucleoside DNA methylation inhibitors, azac-
itidine and decitabine, are used clinically in low doses to
treatmyelodysplastic syndrome, providingproofofprincipal
for epigenetic therapy [81]. Structurally, these agents mimic
cytosine; during cell replication, fake cytosines replace real
cytosines in growing DNA strands and then trap DNA
methyltransferases to interfere with the ability of these
enzymes to reproduce existing methylation in new cells.
While inhibiting DNA methylation is a targeted molecular
approach to therapy, downstream eﬀects on neoplastic
behavior are nonspeciﬁc and may result in cytotoxic cell
death, making predictions of clinical outcomes diﬃcult
[81]. Clinical trials are being extended to test DNMT
inhibitors in solid tumors of the breast, lung, and colon,
in combination with histone deacetylase (HDAC) inhibitors
which provide synergistic beneﬁts in cell studies [82]. Other
treatment avenues on the horizon include induced cellular
programming toguidedevelopmentofepigenetic-modifying
drugs [83].
It has been a little over a decade since the concept of
a CpG island methylator phenotype in colorectal cancer
was introduced, and subsequent focus of several studies on
describing the clinical and pathological features of CIMP
as well as its characterization in tumors has supported
widespread acceptance of the role of DNA methylation
in cancer (Figure 2). The past few years have brought
substantial insights as to the mechanisms underlying the
CIMP pathway in cancer, and the future development of
diagnostics and treatments based on our understanding of
this epigenetic alteration are an exciting development in
epigenetic research.
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